MANAGEMENT OF LDL-C IN HIGH RISK FEMALE PATIENTS WITH ASCVD- A CROSS-SECTIONAL STUDY

Abstract

Therapeutic Area: ASCD/CVD in Women Background: The 2018 ACC/AHA guidelines recommend an LDL-C of 70mg/dL as a threshold to initiate non-statin medications in patients with a history of a major ASCVD event. Analysis of the PINNACLE Registry and the TRANSFORM LDL-C Risk Initiative identified female patients as a high risk population with a low likelihood of achieving an LDL-C 70mg/dL despite having a history of a major ASCVD event, of which only 27% were on the max dose of a high intensity statin. Only 10.4% were noted to be on additional non-statin lipid lowering therapies, of which Ezetimibe was the most prescribed (76.9%) while PCSK9 inhibitors were the least prescribed (7.7%). CVA was the most common observed major ASCVD event (45.8%), while HTN and HLD were the most common associated comorbidities (85.9%, 83.4%). Conclusion: Although the 2018 ACC/AHA guidelines recommend initiating non-statin medications in patients with a major ASCVD event, clinical implementation of these guidelines has not yet become widespread. In this study, we identify female patients as a high risk population that does not meet these guidelines at our institution. Further studies will focus on implementing a quality initiative program to improve the prescribing practices of non-statin medications in this population.